Rachman Ilya M 4

What Happened
Ilya M. Rachman, CEO, Chairman and a director of Immix Biopharma (IMMX), was granted a derivative award covering 500,000 shares on 2026-05-22. The grant is reported at $0.00 (no cash paid at grant) and is recorded as an award/stock option rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-22; filing date (Form 4): 2026-05-29. The filing was submitted 7 days after the transaction date (appears late relative to the 2-business-day Form 4 requirement).
• Grant: 500,000 shares reported as a derivative award at $0.00. The filing does not disclose an exercise price or immediate cash value.
• Vesting: Footnote F1 states the stock option vests in 48 equal monthly installments, contingent on continued service with the company.
• Shares owned after transaction: not specified in the filing.
• Type: Award/Grant (derivative) — this is compensation-related, not an open-market buy or sale.

Context
This was a grant of a stock option award, not an exercise or sale; there was no immediate sale of shares and no cash received. The award vests monthly over four years, so any future transfers or sales will depend on vesting and potential exercise terms. As with most compensation grants, this reflects executive compensation policy rather than a direct market buy/sell signal.